Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease
Status:
COMPLETED
Trial end date:
2024-04-25
Target enrollment:
Participant gender:
Summary
Levodopa-Carbidopa intestinal gel (LCIG) is an effective therapy for complicated Parkinson's disease (PD). Few studies have explored the efficacy and safety of the potential combination of LCIG with catechol-O-methyltransferase (COMT) inhibitors, particularly Opicapone (OPC).
Phase:
NA
Details
Lead Sponsor:
University Hospital of Ferrara
Treatments:
carbidopa, levodopa drug combination Levodopa opicapone